| 1 |
32970826 | Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration. | 2021 May |
1 |
| 2 |
33109037 | A Randomized Study on the Bioequivalence of Desloratadine in Healthy Chinese Subjects and the Association of Different Metabolic Phenotypes With UGT2B10 and CYP2C8 Genotypes. | 2020 |
1 |
| 3 |
30630815 | Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. | 2019 Apr |
5 |
| 4 |
25595597 | A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. | 2015 Apr |
2 |
| 5 |
26135009 | Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor. | 2015 Sep |
1 |